Summary
Previous reports of the Reflex Study 6-month data with rituximab (RTX) indicated that this selective CD20+ B cell targeted therapy can inhibit the radiographic progression of joint structural damage in RA patients with longstanding resistance to one or more TNF inhibitors [Cohen et al. Arthritis Rheum in press).
- rheumatoid arthritis clinical trials
- © 2006 MD Conference Express
Tools
The Reflex Study: Prevention of Joint Structural Damage at 1 Year with Rituximab in Rheumatoid Arthritis Patients with an Inadequate Response to One or More TNF Inhibitors
Permalink:
Table of contents
Cited By...
- No citing articles found.